Prostate Cancer

EDT) (Abstract ID: 2894) - Local secretion of anti-CTLA-4 antibody from a GM-CSF-secreting tumor cell vaccine enhances vaccine efficacy (To be presented in mini-symposia on Sunday, April 2, 3:25 - 3:40 p.m.

EDT) (Abstract ID: 1520) - EGFR inhibitors decrease the potency of GM-CSF-secreting tumor cell vaccines by inhibiting T-cell activation.

(To be presented in a poster discussion on Sunday, April 2, 1:00 - 5:00 p.m.

EDT) (Abstract ID: 1398) - An armed oncolytic vector (OV1203) expressing E.

coli purine nucleoside phosphorylase (PNP) combined with Fludara(TM) shows increased efficacy.

(To be presented in mini-symposia on Tuesday, April 4, 11:40 - 11:55 a.m.

EDT) (Abstract ID: 4022) Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer.

The company is currently pursuing two clinical stage product platforms - GVAX® cancer immunotherapies and oncolytic virus therapies.

Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for ne...

Read more...